Edwards (EW) Gains From Balanced Core Growth and New Launches

Edwards Lifesciences (EW) is benefiting from strength across all product groups. The company’s bullish long-term growth strategy buoys optimism on the stock. The stock currently carries a Zacks Rank #2 (Buy).In December 2023, Edwards announced the strategic decision to spin off the Critical Care segment at the end of 2024. The company expects this tax-free, planned separation to act strategically to its core business. With this spin-off, the company pursues more opportunities for Transcatheter Aortic Valve ...